Literature DB >> 15051512

CpG oligodeoxynucleotide induction of antiviral effector molecules in sheep.

Anil K Nichani1, Radhey S Kaushik, Angelo Mena, Yurij Popowych, Donna Dent, Hugh G G Townsend, George Mutwiri, Rolf Hecker, Lorne A Babiuk, Philip J Griebel.   

Abstract

Immunostimulatory CpG oligodeoxynucleotide (ODN) can protect mice against infection by many pathogens but the mechanisms mediating disease protection are not well defined. Furthermore, the mechanisms of CpG ODN induced disease protection in vivo have not been investigated in other species. We investigated the induction of antiviral effector molecules in sheep treated with a class B CpG ODN (2007). Subcutaneous injection of ODN 2007 induced a dose-dependent increase in serum levels of the antiviral effector molecule, 2'5'-A synthetase. Peak levels of enzyme were observed 4 days following ODN injection and enzyme levels remained elevated for the following 3-5 days. Repeated ODN injections induced a more sustained elevation of serum 2'5'-A synthetase activity. Finally, formulation of ODN 2007 in emulsigen increased the level of serum 2'5'-A synthetase activity and this response was CpG-specific. Elevated serum 2'5'-A synthetase activity suggested that CpG ODN acted through the induction of either interferon (IFN)-alpha or IFN-gamma. ODN 2007 did not induce detectable levels of IFN-alpha or IFN-gamma when incubated with peripheral blood mononuclear cells, but both IFN-alpha and IFN-gamma were detected following stimulation of lymph node cells with ODN 2007. CpG ODN induction of 2'5'-A synthetase in vitro correlated with the secretion of both IFN-alpha and IFN-gamma. Furthermore, immunohistochemical staining of skin revealed a marked cellular infiltration at the site of ODN 2007 injection. This cellular infiltration was CpG-specific and consisted of primarily CD172(+) myeloid cells. Many of the cells recruited to the site of ODN 2007 injection expressed IFN-alpha and some IFN-gamma. These observations support the conclusion that localized cell recruitment and activation contribute to CpG ODN induction of antiviral effector molecules, such as interferon and 2'5'-A synthetase.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15051512     DOI: 10.1016/j.cellimm.2004.01.004

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  5 in total

1.  Identification of a surface protein of Streptococcus suis and evaluation of its immunogenic and protective capacity in pigs.

Authors:  Yuanyi Li; Gabriela Martinez; Marcelo Gottschalk; Sonia Lacouture; Philip Willson; J Daniel Dubreuil; Mario Jacques; Josee Harel
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

2.  Transcriptional profile in afferent lymph cells following vaccination with liposomes incorporating CpG.

Authors:  Melanie R Neeland; Martin J Elhay; David R Powell; Fernando J Rossello; Els N T Meeusen; Michael J de Veer
Journal:  Immunology       Date:  2015-03       Impact factor: 7.397

3.  Intramuscular administration of a synthetic CpG-oligodeoxynucleotide modulates functional responses of neutrophils of neonatal foals.

Authors:  Noah D Cohen; Jessica R Bourquin; Angela I Bordin; Kyle R Kuskie; Courtney N Brake; Kaytee B Weaver; Mei Liu; M Julia B Felippe; Michael H Kogut
Journal:  PLoS One       Date:  2014-10-15       Impact factor: 3.240

4.  Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide.

Authors:  Musheng Bao; Yi Zhang; Min Wan; Li Dai; Xiaoping Hu; Xiuli Wu; Li Wang; Ping Deng; Junzhi Wang; Jianzhu Chen; Yongjun Liu; Yongli Yu; Liying Wang
Journal:  Clin Immunol       Date:  2005-11-17       Impact factor: 3.969

5.  Stimulation with a class A CpG oligonucleotide enhances resistance to infection with feline viruses from five different families.

Authors:  Céline Robert-Tissot; Vera L Rüegger; Valentino Cattori; Marina L Meli; Barbara Riond; Peter F Moore; Monika Engels; Marco Franchini; Regina Hofmann-Lehmann; Hans Lutz
Journal:  Vet Res       Date:  2012-08-20       Impact factor: 3.683

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.